Tags

Type your tag names separated by a space and hit enter

Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action.

Abstract

PURPOSE OF REVIEW

There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward.

RECENT FINDINGS

Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials.

SUMMARY

No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    aDivision of Gastroenterology, Washington University in St. Louis School of Medicine, St. Louis, Missouri bDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota cDepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.

    , ,

    Source

    MeSH

    Abdominal Neoplasms
    Antineoplastic Agents
    Clinical Trials as Topic
    Enteritis
    Humans
    Lactobacillus
    Microbiota
    Mucositis
    Pelvic Neoplasms
    Probiotics
    Radiotherapy

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Review

    Language

    eng

    PubMed ID

    25872116

    Citation

    Ciorba, Matthew A., et al. "Probiotics to Prevent Gastrointestinal Toxicity From Cancer Therapy: an Interpretive Review and Call to Action." Current Opinion in Supportive and Palliative Care, vol. 9, no. 2, 2015, pp. 157-62.
    Ciorba MA, Hallemeier CL, Stenson WF, et al. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care. 2015;9(2):157-62.
    Ciorba, M. A., Hallemeier, C. L., Stenson, W. F., & Parikh, P. J. (2015). Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Current Opinion in Supportive and Palliative Care, 9(2), pp. 157-62. doi:10.1097/SPC.0000000000000134.
    Ciorba MA, et al. Probiotics to Prevent Gastrointestinal Toxicity From Cancer Therapy: an Interpretive Review and Call to Action. Curr Opin Support Palliat Care. 2015;9(2):157-62. PubMed PMID: 25872116.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. AU - Ciorba,Matthew A, AU - Hallemeier,Christopher L, AU - Stenson,William F, AU - Parikh,Parag J, PY - 2015/4/15/entrez PY - 2015/4/15/pubmed PY - 2016/1/28/medline SP - 157 EP - 62 JF - Current opinion in supportive and palliative care JO - Curr Opin Support Palliat Care VL - 9 IS - 2 N2 - PURPOSE OF REVIEW: There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. RECENT FINDINGS: Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. SUMMARY: No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question. SN - 1751-4266 UR - https://www.unboundmedicine.com/medline/citation/25872116/full_citation L2 - http://Insights.ovid.com/pubmed?pmid=25872116 DB - PRIME DP - Unbound Medicine ER -